{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:57Z","timestamp":1791825357049,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00535-025-02342-9","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:51:53Z","timestamp":1768319513000},"page":"195-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis"],"prefix":"10.1007","volume":"61","author":[{"given":"Li","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buer","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2342_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7:e0179.","journal-title":"Hepatol Commun"},{"key":"2342_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bpg.2018.06.004","volume":"34-35","author":"MH Harms","year":"2018","unstructured":"Harms MH, van Buuren HR, van der Meer AJ. Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy. Best Pract Res Clin Gastroenterol. 2018;34\u201335:85\u201394.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2342_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","volume":"39","author":"RE Poupon","year":"2003","unstructured":"Poupon RE, Lindor KD, Par\u00e9s A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12\u20136.","journal-title":"J Hepatol"},{"key":"2342_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644\u20137.","journal-title":"Hepatology"},{"key":"2342_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/apt.17908","volume":"59","author":"BS Hofer","year":"2024","unstructured":"Hofer BS, Burghart L, Halilbasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther. 2024;59:962\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"2342_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII \u2013 Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"key":"2342_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","volume":"77","author":"Q Wang","year":"2022","unstructured":"Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol. 2022;77:1564\u201372.","journal-title":"J Hepatol"},{"key":"2342_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s12072-023-10579-w","volume":"17","author":"Z He","year":"2023","unstructured":"He Z, Wang B, Wu X, et al. Recompensation in treatment-na\u00efve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding. Hepatol Int. 2023;17:1368\u201377.","journal-title":"Hepatol Int"},{"key":"2342_CR9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018;154:2111-21.e8.","journal-title":"Gastroenterology"},{"key":"2342_CR10","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/liv.13878","volume":"38","author":"G Perricone","year":"2018","unstructured":"Perricone G, Duvoux C, Berenguer M, et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver Int. 2018;38:2170\u20137.","journal-title":"Liver Int"},{"key":"2342_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","volume":"16","author":"H You","year":"2022","unstructured":"You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022;16:1\u201323.","journal-title":"Hepatol Int"},{"key":"2342_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3350\/cmh.2019.0010n","volume":"26","author":"KASL clinical practice guidelines for liver cirrhosis","year":"2020","unstructured":"KASL clinical practice guidelines for liver cirrhosis. Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol. 2020;26:83\u2013127.","journal-title":"Clin Mol Hepatol"},{"key":"2342_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"2342_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2025.04.018","volume":"83","author":"M Tonon","year":"2025","unstructured":"Tonon M, Gagliardi R, Pompili E, et al. Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease. J Hepatol. 2025;83:888\u201398.","journal-title":"J Hepatol"},{"key":"2342_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361\u20137.","journal-title":"J Hepatol"},{"key":"2342_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871\u20137.","journal-title":"Hepatology"},{"key":"2342_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","volume":"32","author":"N Momah","year":"2011","unstructured":"Momah N, Silveira MG, Jorgensen R, et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2011;32:790\u20135.","journal-title":"Liver Int"},{"key":"2342_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. Gastroenterology. 2006;130:715\u201320.","journal-title":"Gastroenterology"},{"key":"2342_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/apt.70233","volume":"62","author":"H Lin","year":"2025","unstructured":"Lin H, Zheng M, Huang Y, et al. Lymphocyte-to-Monocyte ratio as a predictor of recompensation in patients with decompensated primary biliary cholangitis. Aliment Pharmacol Ther. 2025;62:646\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"2342_CR20","unstructured":"Goh XE, Goh MX, Chen VL, et al. Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol."},{"key":"2342_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101233","volume":"6","author":"S Piano","year":"2024","unstructured":"Piano S, Reiberger T, Bosch J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 2024;6:101233.","journal-title":"JHEP Rep"},{"key":"2342_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","volume":"74","author":"GM Hirschfield","year":"2021","unstructured":"Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74:321\u20139.","journal-title":"J Hepatol"},{"key":"2342_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000355","volume":"8","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu X, Li S, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: a retrospective study based on Baveno VII criteria. Hepatol Commun. 2024;8:e0355.","journal-title":"Hepatol Commun"},{"key":"2342_CR24","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","volume":"167","author":"M Premkumar","year":"2024","unstructured":"Premkumar M, Dhiman RK, Duseja A, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program. Gastroenterology. 2024;167:1429\u201345.","journal-title":"Gastroenterology"},{"key":"2342_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2025.02.041","volume":"83","author":"Y S\u00e1nchez-Torrijos","year":"2025","unstructured":"S\u00e1nchez-Torrijos Y, Fern\u00e1ndez-\u00c1lvarez P, Rosales JM, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C. J Hepatol. 2025;83:652\u201361.","journal-title":"J Hepatol"},{"key":"2342_CR26","unstructured":"Semmler G, Lens S, Hidalgo \u00c1, et al. Incidence and Clinical Significance of Recompensation After HCV Cure. Clin Gastroenterol Hepatol."},{"key":"2342_CR27","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/tri.13008","volume":"30","author":"AD Aravinthan","year":"2017","unstructured":"Aravinthan AD, Barbas AS, Doyle AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int. 2017;30:1140\u20139.","journal-title":"Transpl Int"},{"key":"2342_CR28","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/liv.15676","volume":"43","author":"BS Hofer","year":"2023","unstructured":"Hofer BS, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int. 2023;43:2220\u201331.","journal-title":"Liver Int"},{"key":"2342_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101496","volume":"7","author":"Y Chen","year":"2025","unstructured":"Chen Y, Wen H, Li Y, et al. Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy. JHEP Rep. 2025;7:101496.","journal-title":"JHEP Rep"},{"key":"2342_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118\u201327.","journal-title":"Hepatology"},{"key":"2342_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357\u201365.","journal-title":"J Hepatol"},{"key":"2342_CR32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","volume":"18","author":"NK Gatselis","year":"2020","unstructured":"Gatselis NK, Goet JC, Zachou K, et al. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2020;18:684-92.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2342_CR33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1872-034X.2009.00550.x","volume":"39","author":"PM Huet","year":"2009","unstructured":"Huet PM, Vincent C, Deslauriers J, et al. Portal hypertension in primary biliary cirrhosis (PBC): a reversible condition? Yes, but not in all UDCA treated patients. Hepatol Res. 2009;39:1032\u20138.","journal-title":"Hepatol Res"},{"key":"2342_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000826","volume":"80","author":"J Ampuero","year":"2024","unstructured":"Ampuero J, Lucena A, Berenguer M, et al. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy. Hepatology. 2024;80:791\u2013806.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02342-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:41:30Z","timestamp":1771659690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02342-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2342"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02342-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}